This article was downloaded by:

On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

Nucleosides Having Quinolone Derivatives as Nitrogenated Base: Regiospecific and Stereospecific Ribosylation of 3-Carbethoxy-1,4-dihydro-4-oxoquinolines

A. D. da Matta^a; A. M. R. Bernardino^a; G. A. Romeiro^a; M. R. P. de Oliveira^a; M. C. B. V. de Souza^a; V. F. Ferreira^a

^a Departamento de Química, Universidade Federal Fluminense, CEP, RJ, Brasil

To cite this Article Matta, A. D. da , Bernardino, A. M. R. , Romeiro, G. A. , de Oliveira, M. R. P. , de Souza, M. C. B. V. and Ferreira, V. F. (1996) 'Nucleosides Having Quinolone Derivatives as Nitrogenated Base: Regiospecific and Stereospecific Ribosylation of 3-Carbethoxy-1,4-dihydro-4-oxoquinolines', Nucleosides, Nucleotides and Nucleic Acids, 15:4,889-898

To link to this Article: DOI: 10.1080/07328319608002135 URL: http://dx.doi.org/10.1080/07328319608002135

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

NUCLEOSIDES HAVING QUINOLONE DERIVATIVES AS NITROGENATED BASE: REGIOSPECIFIC AND STEREOSPECIFIC RIBOSYLATION OF 3-CARBETHOXY-1,4-DIHYDRO-4-OXOQUINOLINES

A. D. da Matta, A. M. R. Bernardino, G. A. Romeiro, M. R. P. de Oliveira, M. C. B. V. de Souza*, V. F. Ferreira

Universidade Federal Fluminense, Departamento de Química Orgânica Outeiro de São João Batista s/nº - Centro - Niterói CEP 24020-150 - RJ, Brasil

ABSTRACT. Ribosylation reactions of previously silvlated 3-carbethoxy-8-methyl-1,4-dihydro-4-oxoquinoline (6a) and 3-carbethoxy-6-methyl-1,4-dihydro-4-oxoquinoline (6b) with 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (7), under Lewis acid catalysis, were studied. The method using hexamethyldisilazane (HMDS)/trimethylchlorosilane (TMCS) mixture for silylation and anhydrous stannic chloride as catalyst for ribosylation failed to give any nucleoside product. On the other hand, the protected nucleoside 3-carbethoxy-6-methyl-1-(2,3,5-tri-O-benzoylβ-D-ribofuranosyl)-1,4-dihydro-4-oxoquinoline (8b) was obtained in good yields using bis(trimethylsilyl)trifluoroacetamide (BSTFA) containing 1% of TMCS and the same catalyst. Compound 8b was more easily isolated in higher yields with an improvement of method chloride laterbγ replacing stannic with trimethylsilyl trifluoromethanesulfonate (TMSOTf).

De-O-benzoylation of 8b with methanolic sodium hydroxide solution afforded the free riboside 3-carbomethoxy-6-methyl-1-β-D-ribofuranosyl-1,4-dihydro-4-oxoquinoline (9b). The structures of the obtained products were confirmed by their UV, MS, IR, ¹H and ¹³C-NMR data.

Quinolones are well known antibacterial substances with great therapeutic importance.¹ Nalidixic acid (1), active against gram negative bacteria, was the first quinolone used in clinical practice for treatment of urinary infections. Ever since, more potent quinolones, with broad spectrum activity, such as norfloxacin (2) and ciprofloxacin (3), have been developed for pharmaceutical use.¹⁻³

$$CH_3$$
 CO_2H
 CO_2H
 CO_2H
 CO_2H

 $2 - R = C_2H_5$

3 - R= cyclopropyl

The synthesis of natural nucleosides analogues has been also intensively investigated during the past years for antiviral and anticancer therapy.⁴

Owing to the important pharmacological effects of both classes of compounds, we decided to synthesize new ribonucleosides having quinolones as nitrogenated base. In this report we will show our results on the regio and stereospecific ribosylation of 3-carbethoxy-8-methyl-1,4-dihydro-4-oxoquinoline (6a) and 3-carbethoxy-6-methyl-1,4-dihydro-4-oxoquinoline (6b).

The quinolone derivatives were synthesized by treatment of *ortho* and *para*-toluidines (4a and 4b, respectively) with diethyl ethoxymethylenemalonate⁵ to obtain the enamine type derivatives diethyl methylanilinomethylenemalonates 5a and 5b in 90 % and 87 % yield, respectively, which were then cyclized in refluxing Dowtherm A⁶ affording 3-carbethoxy-8-methyl-1,4-dihydro-4-oxoquinoline (6a) and 3-carbethoxy-6-methyl-1,4-dihydro-4-oxoquinoline⁵ (6b) in 80 % and 75 % yield, respectively (Scheme I).

Among the various synthetic methods used for nucleoside synthesis the reaction of silylated heterocyclic bases with peracylated sugars, in the presence of a Lewis acid, has become the one most utilized by chemists. Thus, the ribosylation of **6a** and **6b** with 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (7) was investigated using the silylated heterocyclic base method.^{7,8}

However, attempts of silylation of 6a or 6b in a refluxing mixture of HMDS and TMCS followed by removing the reagents excess, and subsequent addition of 7, under anhydrous stannic chloride catalysis, produced only an intractable mixture of products. When the later procedure was modified by replacing hexamethyldisilazane with bis(trimethylsilyl)trifluoroacetamide (BSTFA), at 70°, the protected ribonucleosides 3-carbethoxy-8-methyl-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-1,4-

c) 1- BSTFA or HMDS/TMCS, 2-

SCHEME I

BzŐ

BzÒ 7 ; SnCl4 or TMSOTf

dihydro-4-oxoquinoline (8a) and 3-carbethoxy-6-methyl-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-1,4-dihydro-4-oxoquinoline (8b) were obtained in 5% and 74% yield from 6a and 6b, respectively (method A). The low yield obtained for 8a was probably due to steric hindrance effect from the 8-methyl substituent. Another procedure comprised the use of this same silylation reagent followed by TMSOTf catalysed ribosylation without removing the excess of BSTFA (method B). By method B, the protected ribonucleoside 8b was more easily obtained in a higher yield (81%). Despite this good result, this method also failed to afford 8a from 6a.

De-O-benzoylation was performed by treating 8b with 0.5 N methanolic sodium hydroxide solution for two hours, at room temperature, and then filtering the resulting solution through Dowex 50 H⁺ column⁹ to afford pure 3-carbomethoxy-6-methyl-1-β-D-ribofuranosyl-1,4-dihydro-4-oxoquinoline (8c) in 58 % yield. During this reaction the carbethoxy was transesterified to a carbomethoxy ester group.

The structures of the nucleosides were elucidated by ¹H and ¹³C NMR experiments (¹H, PND, DEPT, ¹H x ¹H-COSY, HMBC, HMQC) and by FAB-HR analysis.

The ribosylation was regiospecific and no trace of reaction at the oxygen site was observed. The anomeric carbon stereochemistry of the nucleoside 8b was assigned by one-dimensional nuclear Overhauser effect difference spectroscopy (nOeds). Upon irradiation of H1' (riboside) H4' increased by 3.2%, establishing β -configuration¹⁰ and confirming the stereoselectivity of the reaction. In addition, H2 signal also increased by 7.1%, establishing the position of ribosylation as N1. These findings can be transferred to 8c.

Carbon chemical shifts for C2 and C4 and for the anomeric carbon (C1') of 8a and 8b were very similar. Furthermore, 8a and 8b afforded UV curves pratically identical, clearly indicating that the ribosylation of 8a also occurred at N1.

EXPERIMENTAL

Melting points were determined on a Fisher-Johns melting point apparatus and are uncorrected. The IR spectra were recorded on a Perkin-Elmer 1420 spectrometer as potassium bromide pellets and frequencies are expressed in cm⁻¹. Mass spectra were obtained using VG Autospec and VG-ZAB-E spectrometers. UV spectra were recorded on a UV 160A Shimadzu spectrophotometer. ¹H and ¹³C NMR spectra were acquired on Bruker AC-300, Varian Unity Plus-300 and Varian VXR-500 instruments, in solvents specified. Chemical shifts are reported in ppm (δ) relative to tetramethylsilane as an internal standard.

Proton and carbon spectra were typically obtained at room temperature. The two dimensional experiments were acquired using standard Varian Associates automated programs for data acquisition and processing. Nuclear Overhauser experiments were carried out at 299.94 MHz with a spectral window of 4000 Hz with a pulse flip of 45°,

acquisition time of 3.744 seconds and 5.0 seconds relaxation delay using gated decoupling.

General Procedure for diethyl methylanilinomethylenemalonates (5a and 5b)

A solution of *ortho* or *para*-toluidine (10.7 g, 100 mmoles), and 20.4 ml (100 mmoles) of diethyl ethoxymethylenemalonate was heated under reflux for 3 hours. The mixture was allowed to cool, then poured into ice-cold water (100 g). The precipitate was collected by filtration and recrystallized from hexane to give:

5a: 24.93 g (90 %) as white crystals, mp 63 °C (lit. mp 63 °C; IR 1675 and 1635 (C=O), 1240 (C-O); MS: m/z (relative intensity) 277 (M⁺, 100), 231 (85), 175 (30), 130 (48), 91 (29); ¹H-NMR (CDCl₃, 200.13 MHz) δ 11.12 (d, 1H, J= 12.9 Hz, NH), 8.55 (d, 1H, J= 13.5 Hz, Hβ), 7.26-7.18 (m, 1H, H6), 7.10-7.06 (m, 3H, H3-H5), 4.38-4.19 (m, 4H, (O-CH₂), 2.37 (s, 3H, methyl), 1.42-1.28 (m, 6H, CH₂CH₃); ¹³C-NMR (CDCl₃, 50.0 MHz) δ 166.7 (C=O), 165.2 (C=O), 151.6 (Cβ), 137.4 (C1), 126.7 (C2), 130.7, 126.9, 126.7, 124.3 and 114.7 (C3-C6), 93.2 (Cα), 59.8 (OCH₂), 59.5 (OCH₂), 16.9 (CH₃-C2), 14.0 (CH₂CH₃), 13.9 (CH₂CH₃).

5b: 24.10 g (87 %) as white crystals, mp 46-48 °C (lit.⁵ mp 48 °C); IR 1715 and 1685 (C=O), 1250 (C-O); MS: m/z (relative intensity) 277 (M⁺, 87), 231 (100), 175 (56), 130 (30), 91 (24); ¹H-NMR (CDCl₃, 200.13 MHz) δ 10.96 (d, 1H, J= 13.1 Hz, NH), 8.48 (d, 1H, J= 13.9 Hz, Hβ), 7.15 (d, 2H, J= 8.2 Hz, H2,6 or H3,5), 7.01 (d, 2H, J= 8.2 Hz, H2,6 or H3,5), 4.33-4.16 (m, 4H, O-CH₂), 2.31 (s, 3H, methyl), 1.39-1.26 (m, 6H, CH₂CH₃); ¹³C-NMR (CDCl₃, 50.0 MHz) 168.8 (C=O), 165.4 (C=O), 151.7 (Cβ), 136.5 (C1), 134.4 (C4), 130.0 (C3,5), 116.8 (C2,6), 92.6 (Cα), 59.9 (O-CH₂), 59.7 (O-CH₂), 20.4 (CH₃-C4), 14.1 (CH₂CH₃), 14.0 (CH₂CH₃).

General Procedure for 3-carbethoxy-8-methyl-1,4-dihydro-4-oxoquinoline (6a) and 3-carbethoxy-6-methyl-1,4-dihydro-4-oxoquinoline (6b)

To 10 ml of refluxing Dowtherm A, 3g (10.83 mmoles) of diethyl methylanilinomethylenemalonate (5a or 5b) was added. The resulting mixture was heated

at reflux under nitrogen for 1.15 h. After the mixture had cooled the precipitate was collected by filtration, washed with petroleum ether and methylene chloride and recrystallized from glacial acetic acid to give:

6a: 2.00 g (80 %) as white crystals, mp 258 °C (lit. mp 259 °C); IR 3300-2800 (OH/NH), 1690 (C=O), 1285 (C-O); MS: m/z (relative intensity) 231 (M⁺, 42), 185 (100), 129 (41); ¹H-NMR [(CD₃)₂SO, 300.13 MHz] δ 11.62 (s, 1H, NH), 8.40 (s, 1H, H2), 8.10 (d, 1H, J= 7.2 Hz, H5), 7.55 (d, 1H, J= 7.0 Hz, H7), 7.25 (t, 1H, J= 7.2 Hz, H6), 4.22 (q, 2H, J= 7.1 Hz, O-CH₂), 2.50 (s, 3H, methyl), 1.25 (t, 3H, J= 7.1 Hz, CH₂CH₃); ¹³C-NMR [(CD₃)₂SO, 75.0 MHz] 174.5 (C4), 165.7 (O=CO), 145.4, 138.4, 134.1, 128.4, 127.9, 125.2, 124.5, 110.6 (C2, C3, C5-C8, C4a, C8a), 60.5 (O-CH₂), 17.9 (CH₃-C8), 15.2 (CH₂CH₃).

6b: 1.88 g (75 %) as white crystals, mp 267-268 °C (lit.⁵ mp 268 °C); IR 3300-2800 (OH/NH), 1695 (C=O), 1290 (C-O); ¹H-NMR [(CD₃)₂SO, 300.13 MHz] 11.9 (bs, 1H, NH), 8.40 (s, 1H, H2), 7.95 (s, 1H, H5), 7.50 (s, 2H, H7 and H8), 4.30 (q, 2H, J= 7.2 Hz, O-CH₂), 2.40 (s, 3H, methyl) 1.30 (t, 3H, J= 7.2 Hz, CH₂CH₃); ¹³C-NMR [(CD₃)₂SO, 75.0 MHz] 172.7 (C4), 164.4 (O=CO), 143.5 (C2), 136.6 (C8a), 126.9 (C5), 124.5 (C3), 118.1 (C7 or C8), 133.5, 132.9, 109.6 (C6, C4a, C7 or C8), 58.9 (O-CH₂), 20.2 (CH₃C6), 13.8 (CH₂CH₃).

3-Carbethoxy-8-methyl-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-1,4-dihydro-4-oxo-quinoline (8a)

Method A: Using BSTFA/TMCS, and anhydrous SNCl₄ catalysis

A stirred solution of 3-carbethoxy-dihydro-8-methyl-1,4-dihydro-4-oxoquinoline (6a) (0.100 g, 0.43 mmol), BSTFA (0.23 ml, 0.86 mmol) containing 1% TMCS was heated at 70 °C, under nitrogen, for 4 h. Excess was removed under reduced pressure. To the resulting product was added a solution of 1-O-acetyl-2,3,5-tri-O-benzoyl-β-D-ribofuranose (7) (0.159 g, 0.31 mmol) in 50 ml of 1,2-dichloroethane, followed by dropwise addition of anhydrous stannic chloride (a solution of 0.046 ml, 0.39 mmol in 2

ml of 1,2-dichloroethane). After the mixture had been stirred for 4 h at room temperature, 1,2-dichloroethane (10 ml) was added. The resulting mixture was filtered and washed with saturated sodium bicarbonate solution (3 x 20 ml). After drying over anhydrous magnesium sulfate, the solvent was removed under reduced pressure giving an oil which was purified by preparative cromatography on silica gel plates (20 x 20 cm), eluted with methylene chloride: ethyl acetate (6:4), to give 10.65 mg (5 %) of 8a as a white viscous oil; UV λ_{max} (CH₃OH) 316 nm (ϵ 12875), 228 (ϵ 63061); IR (neat) 1720 (C=O), 1270 (C-O); 1 H-NMR (CDCl₃, 300.13 MHz) δ 8.82 (s, 1H, H2), 8.34 (d, 1H, J= 8.0 Hz, H5), 8.20 (d, 2H, J= 8.0 Hz, H2"), 7.95 (d, 2H, J= 7.8 Hz, H2"), 7.75 (d, 2H, J= 8.0 Hz, H2"), 7.65-7.25 (m, 11H, H6, H7, H3", H4"), 6.65 (d, 1H, J= 6.0 Hz, H1'), 5.95-5.82 (m, 2H, H2', H3'), 4.85-4.70 (m, 3H, H4', H5'), 4.25-4.00 (m, 2H, O-CH₂), 2.80 (s, 3H, methyl), 1.30-1.20 (m, 3H, CH₂CH₃); ¹³C-NMR (CDCl₃, 75.0 MHz) δ 174.9 (C4), 164.8 (O=C-C3), 166.0 (C2'-O-C=O), 164.5 (C3'-O-C=O), 164.0 (C5'-O-C=O), 145.4 (C2), 140.0, 137.0, 133.7, 133.4, 130.3, 129.6, 129.5, 128.9, 128.6, 128.4, 128.3, 127.8, 125.9, 125.4, 125.1, 113.6 (aromatic carbons), 90.3 (C1'), 80.0 (C4'), 74.4 (C2'), 71.0 (C3'), 63.8 (C5'), 60.6 (O-<u>C</u>H₂), 22.0 (<u>C</u>H₃-C8), 14.1 (CH₂<u>C</u>H₃).

3-Carbethoxy-6-methyl-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-1,4-dihydro-4oxoquinoline (8b)

Method A: Using BSTFA/TMCS and anhydrous SnCl₄ catalysis

Compound 8b was obtained as described for 8a, using 0.720g (3.11 mmoles) of 3-carbethoxy-6-methyl-1,4-dihydro-4-oxoquinoline (6b), 2 ml (7.39 mmoles) of BSTFA containing 1% of TMCS, a solution of 1.27 g (2.5 mmoles) of 7 in 26 ml of 1,2-dichloroethane, and a solution of 0.36 ml (3.1 mmoles) of anhydrous stannic chloride in 7 ml of 1,2-dichloroethane. The nucleoside 8b was isolated as a white solid which was recrystallized from ethanol to give 1.26 g (74%) of white crystals, mp 186 °C; UV λ_{max} (CH₃OH) 319 nm (ϵ 11356), 229 (ϵ 56204); IR 1720 (C=O), 1260 (C-O); high resolution MS (FAB) m/z: calcd for C₃₉H₃₄NO₁₀ (M+H)⁺ 676.2183. Found 676.2173; ¹H-NMR (CDCl₃, 300.13 MHz) δ 8.89 (s, 1H, H2), 8.26 (s, 1H, H5), 8.10 (d, 2H, J= 8.5 Hz, H2"),

7.96 (d, 2H, J= 8.5 Hz, H2"), 7.93 (d, 2H, J= 8.5 Hz, H2"), 7.65-7.33 (m, 11H, H7, H8, H3", H4"), 6.51 (d, 1H, J= 5.0 Hz, H1'), 6.01 (t, 1H, J= 5.0 Hz, H2'), 5.91 (t, 1H, J= 5.0 Hz, H3'), 4.96-4.80 (m, 3H, H4', H5'), 4.28-4.02 (m, 2H, O-C $\underline{\text{H}}_2$), 2.42 (s, 3H, methyl), 1.30-1.20 (m, 3H, CH₂C $\underline{\text{H}}_3$); ¹³C-NMR (CDCl₃, 75.0 MHz) δ 174.4 (C4), 165.1 (O= $\underline{\text{C}}$ -C3), 166.1 (C2'-O- $\underline{\text{C}}$ =O), 164.8 (C3'-O- $\underline{\text{C}}$ =O), 164.7 (C5'-O- $\underline{\text{C}}$ =O), 142.6 (C2), 127.9 (C5), 114.6 (C7 or C8), 136.4, 135.5, 134.1, 133.9, 133.8, 133.6, 129.9, 129.8, 129.7, 128.7, 128.6, 128.4, 128.2 and 111.8 (aromatic carbons), 90.4 (C1'), 80.9 (C4'), 74.4 (C2'), 70.8 (C3'), 63.4 (C5'), 60.7 (O- $\underline{\text{C}}$ H₂), 20.9 ($\underline{\text{C}}$ H₃-C6), 14.3 (CH₂ $\underline{\text{C}}$ H₃).

<u>Method B</u>: Using BSTFA/TMCS and trimethylsilyl trifluoromethanesulfonate (TMSOTf) catalysis

A stirred solution of 3-carbethoxy-6-methyl-1,4-dihydro-4-oxoquinoline (6b) (0.400 g, 1.73 mmoles in 6.0 ml of acetonitrile) and BSTFA (2.0 ml, 7.39 mmoles) containing 1% of TMCS was heated at 70 °C, under nitrogen, for 2 h. The resulting mixture was allowed to cool and a solution of compound 7 in 6.0 ml of acetonitrile was added, followed by dropwise addition of TMSOTf (0.42 ml, 2.20 mmoles, in 1.0 ml of acetonitrile). Stirring was continued for an additional 3 h, at room temperature, and then the solution was poured into ice-cold water (15 g). The resulting mixture was extracted with methylene chloride (3 x 20 ml) and the combined organic phases were washed with a saturated sodium bicarbonate solution (3 x 20 ml) and water (3 x 20 ml). After drying over anydrous magnesium sulfate, the solvent was removed under reduced pressure to leave the product as white crystals which were recrystallized from ethanol to give pure 8b (0.950 g, 81%).

3-Carbomethoxy-6-methyl-1-\(\beta\)-D-ribofuranosyl-1,4-dihydro-4-oxoguinoline (8c)

A mixture of 8b (0.400 g, 0.59 mmol) in 0.5 N methanolic sodium hydroxide (30 ml) was stirred for 2 h at room temperature, under nitrogen. The resulting solution was passed through a column of Dowex 50 H⁺ (20 ml) previously washed with methanol:water mixture (3:1). The filtrate was evaporated furnishing a solid which was partitioned between water and ethyl ether. The aqueous solution was evaporated under

reduced pressure to give 0.120 g of 8c (58 %), as white crystals, mp 218 °C; IR 3650-3000 (OH), 1690 (C=O), 1200 (C-O); high resolution MS (FAB) m/z: calcd for $C_{17}H_{20}NO_7$ (M+H)⁺ 350.1240. Found 350.1233; ¹H-NMR (CD₃OD, 300.13 MHz) δ 9.40 (s, 1H, H2), 8.20 (d, 1H, J= 1.5 Hz, H5), 7.73 (d, 1H, J= 8.5 Hz, H8), 7.65 (dd, 1H, J= 8.5 and 1.5 Hz, H7), 6.15 (d, 1H, J= 5.0 Hz, H1'), 4.25-4.20 (m, 3H, H2', H3', H4'), 4.05 (d, 1H, J= 7.0 Hz, H5'), 3.85 (d, 1H, J= 7.0 Hz, H5', 3.80 (s, 3H, O-CH₃), 2.45 (s, 3H, methyl); ¹³C-NMR (CD₃OD, 75.0 MHz) δ 176.8 (C4), 167.0 (O=C-C3), 145.2, 138.2, 137.1, 135.6, 129.1, 127.4, 117.5, 110.7 (aromatic carbons) 94.2 (C1'), 86.1 (C4'), 76.8 (C2'), 70.6 (C3'), 61.4 (C5'), 52.0 (O-CH₃), 21.0 (CH₃-C6).

Acknowledgements

The financial support of CNPq (PADCT 620587/91-1, Brazil), CNPq-PIBIC (Brazil) and CAPES (Brazil) is gratefully acknowledged. We thank Prof. Dr. Francis James Schmitz (University of Oklahoma, USA) for NMR and MS spectra. We also thank Dr. Lothar Bergter (Brazil), Dr. Maria Fernanda Vasconcelos da Cunha (Universidade Federal Fluminense, Brazil) and Prof. Cesar Dantas de Oliveira (Universidade Federal Fluminense, Brazil) for useful advice.

References

- 1. L. A. Mitscher, R. M. Zavod, P. V. Devasthale, D. T. W. Chu, L. L. Shen, P. N. Sharma and A. G. Pernet, Chemtech, 50 (1991).
- 2. E. R. Bacon and S. J. Daum, <u>J. Heterocycl. Chem.</u>, 28, 1953 (1991).
- 3. S. Gubert, C. Braojos, L. Anglada, J. Bolós and C. Palacin, <u>J. Heterocycl. Chem.</u>, 29, 55 (1992).
- C. Périgaud, G. Gosslin and J. L. Imbach, <u>Nucleosides & Nucleotides</u>, 11, 903 (1992).

- 5. G. F. Duffin and J. D. Kendall, <u>J. Chem. Soc.</u>, 893 (1948).
- 6. C. C. Price and R. M. Roberts, J. Am. Chem. Soc., 68, 1204 (1946).
- 7. U. Niedballa and H. Vorbruggen, J. Org. Chem., 39, 3654 (1974).
- E. Lukevics and A. Zablocka, <u>Nucleoside Synthesis</u>; J. Mellor, Ed.; Ellis Horwood: New York, NY; 1991.
- 9. U. Niedballa and H. Vorbruggen, J. Org. Chem., 39, 3668 (1974).
- 10. H. Rosemeyer, G. Tóth and F. Seela, Nucleosides & Nucleotides, 8, 587 (1989)

Received July 2, 1995 Accepted November 8, 1995